Figure 1. ZIKV extends survival of glioma-bearing mice.
(A) Scheme of experiments. C57BL6/J mice were implanted with 4 × 104 GL261 or CT2A glioma cells transduced with luciferase and treated intratumorally with 105 FFU mouse-adapted ZIKV-Dakar or PBS control on day 7. (B and C) Survival analysis of mice bearing GL261 (n = 19–21 mice) (B) or CT2A (n = 16–17) (C). (D–G) Images of hematoxylin and eosin staining of coronal brain sections at 7 and 14 days after ZIKV treatment. Scale bars: 1000 μm (top), 50 μm (bottom). Arrows indicate immune cells. Statistical differences were determined by (B and C) log-rank test: ***P < 0.001. All data are pooled from at least 2 to 3 independent experiments.